COVID-19

Innovation Council sat down with Julia Spencer, Associate Vice President for Global Multilateral Engagement & Strategic Alliances at MSD, to discuss the development, manufacture, and broad global diffusion of the company’s COVID-19 therapeutic, molnupiravir. The interview touches on a range of topics, including the risks taken by innovators to scale manufacturing as rapidly as possible, voluntary licensing and the establishment of global production networks to ensure adequate global supply, the critical importance of demand forecasting, and factors such as lack of testing that impacted the uptake of molnupiravir in some countries.

Merck Life Science has released a paper on trends in vaccine manufacturing in the Asia Pacific Region. The paper includes research from interviews with nearly forty industry executives, plus interviews from research institutes in ten different countries. The COVID pandemic highlighted the potential of mRNA vaccines, with 87% of respondents looking to focus on mRNA vaccines as a critical modality in the future. Furthermore, survey respondents cited process development and technology transfer expertise as key needs when adopting new technology. Merck Life Science considers that it will be some time before mRNA becomes the dominant modality, given the need for production processes and the regulatory landscape to evolve in the meantime. The company expects that most vaccine producers will want to have capabilities relating to multiple vaccine modalities, as they invest to expand facilities and incorporate bioprocessing 4.0.

Click here to read the full paper.

To raise awareness about the different forms of voluntary collaborations, particularly those related to technology transfer, IFPMA hosted a working lunch in Geneva in June.  

Several partners shared insights and experiences about their COVID-related manufacturing partnerships. The discussion touched on the types of bottlenecks that slowed the pandemic response – and how these can be tackled in the coming months. 

Particularly fascinating is the part of the session starting at minute 46 where the panel discussion with industry experts begins.

Click here to watch the video of the event

Innovation Council submitted these perspectives to the ITC investigation of COVID-19 Diagnostics and Therapeutics and Flexibilites under the TRIPS Agreement.

The Geneva Network recently published analysis about the benefits from voluntarily licensing in the health space. The author argues that voluntary licensing was crucial during COVID-19, aiding the quick and large scale production of vaccines and therapeutics. Overall, it is noted that voluntary licensing can enable long term knowledge transfer, cooperation between companies, and increased flexibility and speed in the innovation process.

Click here to read the full story.

WIPO has released the 2022 Global Innovation Index with Switzerland once again placing first, for a 12th year in a row. The United States has climbed to take second position and the United Kingdom has stayed in fourth, the same as in 2021. Even though there was an expectation for a decrease in R&D after the COVID-19 pandemic, this has not been the case for many of the large corporate companies, with there being an almost 10% increase in R&D in 2021, reaching a figure of over $900 billion in 2021. Some countries increased their R&D budget spending for 2021, such as Germany, while other such as Japan and the United States didn’t. Intellectual Property filling also continued to increase in 2021 with a rise of 15%. Data was also found that 26 countries are outperforming their development with innovation, including countries such as India and Indonesia.

The Global Innovation Index predicts two new innovation waves to come, contradicting those who believe innovation driven growth is going to stay at a low. The Digital Age innovation wave and the Deep Science innovation wave are predicted to be the next two biggest breakthroughs in innovation, but it is well accepted that these will take time. The Digital Age innovation wave would focus on automation and artificial intelligence, while the Deep Science innovation wave is thought to look at bio- and nanotechnologies which would revolutionise science.

Click here to read the full report.

Preparing for the next pandemic is a priority for many national public-health leaders and requires them to lay the groundwork to mount an effective vaccine response.

Decision makers could set the stage for vaccine resilience by defining what their countries and regions need; assessing the local capacity to scale production of vaccine doses; identifying gaps and weaknesses in their national and regional vaccine value chains.

Read the full article here.